CytomX Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CytomX Therapeutics, Inc. (CTMX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $4.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $16.16M, a 69.17% increase year-over-year.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $9.55M, a 49.76% decline year-over-year.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $19.01M.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$137.29M.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$24.89M, a 218.55% decline from fiscal 2024.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $20.99M.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$176.48M.
- CytomX Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$11.88M, a 186.90% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.56M 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $16.16M 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | -$24.89M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | -$3.87M 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $10.99M 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | $9.55M 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | $20.99M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $23.52M 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | $26.08M 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $19.01M 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | -$176.48M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$167.63M 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | -$136.11M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | -$137.29M 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | -$11.88M 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | -$110.50M 10-Q · filed 2023-11-07 | -$110.49M 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | -$76.24M 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | -$42.04M 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | $13.67M 10-K/A · filed 2023-03-27 | ||||
| 2021-09-30 | $44.42M 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $64.29M 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $137.81M 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $3.43M 10-K/A · filed 2023-03-27 | ||||
| 2020-09-30 | -$11.62M 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $102.96M 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | -$45.14M 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | -$59.15M 10-K/A · filed 2023-03-27 | ||||
| 2019-09-30 | -$82.93M 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | -$98.19M 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | -$57.17M 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $70.03M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $82.20M 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | -$44.64M 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | -$35.39M 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | $72.90M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $44.82M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |